DIRECT MEDICAL COSTS AND HEALTH CARE RESOURCE USE ASSOCIATED WITH HEPATIS C INFECTION IN PORTUGAL

Author(s)

Laires P1, Pereira R2, Calinas F3, Marinho RT4, Martins AP11Merck, Sharp & Dohme, Oeiras, Portugal, 2Merck Sharp & Dohme, Lda., LISBON, Portugal, 3Hospital de Santo António dos Capuchos, Lisbon, Portugal, 4Hospital Santa Maria, Lisbon, Portugal

OBJECTIVES: To calculate the direct medical costs associated with HCV health states by eliciting expert opinion. METHODS: Portuguese-specific annual direct medical costs of HCV health states were estimated based on a national expert panel with 8 clinicians experienced in HCV treatment at the national level. We adopted a two-stage modified Delphi technique: First, experts independently answered questions concerning the resource use associated with each HCV-related health state. Secondly, a consensus meeting was held where experts were encouraged to revise their earlier answers after the panel discussion. The annual cost for each health state of HCV disease was thereafter obtained by multiplying unit costs with the consensus scores for each resource use. Unitary costs were obtained through national official sources. Fibrosis (F0-F3), compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and liver transplantation were set as the different HCV health states with relevance for clinical and economic research. RESULTS: Estimated annual costs per HCV health state were the following: fibrosis (F0-F3) was €580, in advanced liver disease, CC was €1,156, whereas DC was €8,222 for the first year and €9,085 for subsequent years. For HCC first year, the annual cost was €20,749, whilst €19,088 for subsequent years. For liver transplant, first year cost was €112,072, while for subsequent years it was €7,558. The considerable difference between the costs associated with the first and subsequent years is due to the transplant procedure being the cost driver for this health state. CONCLUSIONS: Overall Cost of illness associated with HCV infection is substantial in Portugal and increases throughout the liver disease health states. Strategies aiming to treat HCV infection have the potential to decrease the disease progression and subsequent total costs associated with HCV-related liver disease. The results from our research highlight this point and may support cost-effectiveness analysis in the evaluation of those strategies.

Conference/Value in Health Info

2012-11, ISPOR Europe 2012, Berlin, Germany

Value in Health, Vol. 15, No. 7 (November 2012)

Code

PIN73

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×